Compare Direxion Daily TSLA Bull 2X Shares (TSLL) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Direxion Daily TSLA Bull 2X Shares vs Zoetis Inc — how do they compare? Direxion Daily TSLA Bull 2X Shares trades at $9.76, while Zoetis Inc trades at $73.65 (market cap $30.40B). The key difference: Zoetis Inc pays a 2.88% dividend while Direxion Daily TSLA Bull 2X Shares pays none, and Direxion Daily TSLA Bull 2X Shares is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.
| TSLL | ZTS | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $23.03 | $150.61 |
52-Week Low | $6.74 | $71.91 |
Market Cap | — | $30.40B |
Enterprise Value | — | $37.96B |
Dividend Yield | — | 2.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TSLL (Direxion Daily TSLA Bull 2X Shares ETF) trades at $9.87, up 7.87% on strong Tesla momentum ahead of the Cybercab event. The technical outlook is bullish with moving averages supporting upward momentum, while oscillators remain neutral. Recent news highlights investor enthusiasm for leveraged Tesla exposure, though the ETF's structure amplifies volatility risks.
The outlook remains driven by Tesla's performance, with potential upside from product launches but significant risk from daily rebalancing effects. Investors face amplified gains or losses relative to Tesla, requiring careful risk management given the ETF's leveraged structure and Tesla's inherent stock volatility.
Zoetis (ZTS) trades at $73.6, down 2.92% on the day, near its 52-week low amid bearish technical signals. The stock shows strong fundamentals with a P/E of 12, net margin of 27.69%, and consistent earnings beats, but faces headwinds from weak U.S. companion animal sales and reduced 2026 guidance. Recent news includes an FDA emergency use authorization for Simparica Trio and participation in healthcare conferences.
The outlook is mixed: valuation appears attractive with a consensus price target of $93.40, but near-term risks include competitive pressures and soft pet health demand. Long-term investors may find value in its profitability and market dominance, though volatility persists from sector challenges and investor sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Direxion Daily TSLA Bull 2X Shares
TSLL provides 200% of the daily performance of Tesla, Inc. (TSLA). It uses swaps and financial derivatives to achieve its 2x leverage, making it a high-volatility tool for tactical trading rather than long-term investment due to daily resets.
Read more on TSLL →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
